LONG BEACH, Calif. / Mar 16, 2023 / Business Wire / Molina Healthcare, Inc. (NYSE: MOH) today announced details for the release of its results for the first quarter ending March 31, 2023.
Molina Healthcare will issue its earnings release for the first quarter ending March 31, 2023, after the market closes on Wednesday, April 26, 2023, and will host a conference call and webcast to discuss the earnings release on Thursday, April 27, 2023, at 8:00 a.m. Eastern Time. To access this interactive teleconference, dial (877) 883-0383 and enter the confirmation number, 1543593. A telephonic replay of the conference call will be available through Thursday, May 4, 2023, by dialing (877) 344-7529 and entering the confirmation number, 5745408.
A live broadcast of Molina Healthcare’s conference call will be available on the Company’s website, molinahealthcare.com. A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast.
2023 Virtual Investor Day
The Company also announced it will host a Virtual Investor Day meeting on Monday, May 15, 2023, beginning at 8:30 a.m. Eastern Time.
Investors can register for the event at www.molinahealthcareinvestorday.com/2023.
A 30-day online replay of the Investor Day meeting will be available approximately one hour following the conclusion of the live webcast.
About Molina Healthcare
Molina Healthcare, Inc., a FORTUNE 500 company (currently ranked 125), provides managed healthcare services under the Medicaid and Medicare programs and through the state insurance marketplaces. Through its locally operated health plans, Molina Healthcare served approximately 5.3 million members as of December 31, 2022. For more information about Molina Healthcare, please visit molinahealthcare.com.
| Last Trade: | US$166.90 |
| Daily Change: | 6.38 3.97 |
| Daily Volume: | 1,512,713 |
| Market Cap: | US$8.580B |
November 14, 2025 October 22, 2025 | |

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load